{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:10:07Z","timestamp":1783937407403,"version":"3.55.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpagonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric and Adolescent Gynecology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jpag.2012.05.011","type":"journal-article","created":{"date-parts":[[2012,8,27]],"date-time":"2012-08-27T01:56:39Z","timestamp":1346032599000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gynecologic and Reproductive Health Concerns of Adolescents Using Selected Psychotropic Medications"],"prefix":"10.1016","volume":"26","author":[{"given":"Hina J.","family":"Talib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Alderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpag.2012.05.011_bib1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/CHI.0b013e3181ae0a08","article-title":"Practice parameter on the use of psychotropic medication in children and adolescents","volume":"48","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4088\/JCP.11r07064","article-title":"Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics","volume":"72","author":"Correll","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archpedi.157.1.17","article-title":"Psychotropic practice patterns for youth: a 10-year perspective","volume":"157","author":"Zito","year":"2003","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.jpag.2012.05.011_bib4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/adc.2004.050468","article-title":"Increased prescribing trends of paediatric psychotropic medications","volume":"89","author":"Wong","year":"2004","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jpag.2012.05.011_bib5","first-page":"124","article-title":"First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents","volume":"19","author":"Panagiotopoulos","year":"2010","journal-title":"Can Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib6","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"47","author":"Correll","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second generation antipsychotic medications during first time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jpag.2012.05.011_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1399-5618.2010.00798.x","article-title":"Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo controlled trials","volume":"12","author":"Correll","year":"2010","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jpag.2012.05.011_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11592020-000000000-00000","article-title":"Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials","volume":"34","author":"Pringsheim","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.jpag.2012.05.011_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1196\/annals.1429.030","article-title":"Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents","volume":"1135","author":"Joffe","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jpag.2012.05.011_bib13","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1037\/a0019632","article-title":"Psychiatric disorders and sexual risk among adolescents in mental health treatment","volume":"78","author":"Brown","year":"2010","journal-title":"J Consult Clin Psychol"},{"key":"10.1016\/j.jpag.2012.05.011_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.jpag.2012.05.011_bib16","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.jpag.2012.05.011_bib17","series-title":"Pediatric Psychopharmacology","first-page":"313","article-title":"Antipsychotic agents: traditional and atypical","author":"Correll","year":"2011"},{"key":"10.1016\/j.jpag.2012.05.011_bib18","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","article-title":"Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study","volume":"70","author":"Findling","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib19","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.jpag.2012.05.011_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/cap.2008.0120","article-title":"Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects","volume":"19","author":"Roke","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jpag.2012.05.011_bib21","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jpag.2012.05.011_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/cap.2004.14.350","article-title":"A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents","volume":"14","author":"Saito","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jpag.2012.05.011_bib24","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/00004583-200212000-00015","article-title":"Effects of development on olanzapine-associated adverse events","volume":"41","author":"Woods","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/syn.890010503","article-title":"Human brain dopamine receptors in children and aging adults","volume":"1","author":"Seeman","year":"1987","journal-title":"Synapse"},{"key":"10.1016\/j.jpag.2012.05.011_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chc.2005.08.006","article-title":"Female puberty: clinical implications for the use of prolactin modulating psychotropics","volume":"15","author":"Becker","year":"2006","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.jpag.2012.05.011_bib27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib28","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.161.5.918","article-title":"Growth and sexual maturation during long-term treatment with risperidone","volume":"161","author":"Dunbar","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v64n0704","article-title":"Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients","volume":"64","author":"Becker","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4088\/JCP.08m04595gre","article-title":"A cross-sectional evaluation of the effect of risperidone and selective seratonin reuptake inhibitors on bone mineral density in boys","volume":"71","author":"Calarge","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib31","first-page":"234","article-title":"Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth","volume":"20","author":"Ho","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","article-title":"Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jpag.2012.05.011_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/104454602760219126","article-title":"Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine","volume":"12","author":"Alfaro","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jpag.2012.05.011_bib34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.pnpbp.2010.03.035","article-title":"Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole","volume":"34","author":"Lian","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/104454601317261618","article-title":"Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children","volume":"11","author":"Cohen","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jpag.2012.05.011_bib36","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1592\/phco.26.6.748","article-title":"Atypical antipsychotics and pituitary tumors: a phmacoviginlance study","volume":"26","author":"Szarfman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpag.2012.05.011_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/104454604773840517","article-title":"Atypical antipsychotic use in a state hospital inpatient adolescent population","volume":"14","author":"Kelly","year":"2004","journal-title":"J Child and Adolesc Psychopharmacol"},{"key":"10.1016\/j.jpag.2012.05.011_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jadohealth.2008.11.010","article-title":"Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents","volume":"45","author":"Jerrell","year":"2009","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.jpag.2012.05.011_bib39","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.4088\/JCP.v66n1019e","article-title":"Thyroid dysfunction during treatment with atypical antipsychotics","volume":"66","author":"Greenspan","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib40","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1507\/endocrj.K10E-216","article-title":"Menstrual disturbances in various thyroid diseases","volume":"57","author":"Kakuno","year":"2010","journal-title":"Endocr J"},{"key":"10.1016\/j.jpag.2012.05.011_bib41","first-page":"53","article-title":"Excessive Uterine Bleeding","volume":"23","author":"Talib","year":"2012","journal-title":"Adolesc Med"},{"key":"10.1016\/j.jpag.2012.05.011_bib42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4088\/JCP.v66n0111","article-title":"Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone or fluphenazine","volume":"66","author":"Kelly","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib43","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1007\/BF03348825","article-title":"Effects of lithium treatment on hypothalamic-pituitary-thyroid axis","volume":"16","author":"Lombardi","year":"1993","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jpag.2012.05.011_bib44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.beem.2009.06.002","article-title":"Lithium and thyroid","volume":"23","author":"Lazarus","year":"2009","journal-title":"Best Pract Clin Endocrinol Metab"},{"key":"10.1016\/j.jpag.2012.05.011_bib45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00004583-200402000-00018","article-title":"Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium","volume":"43","author":"Gracious","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib46","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/01.CHI.0000070247.24125.24","article-title":"Lithium treatment of acute mania in adolescents: a large open trial","volume":"42","author":"Kafantaris","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib47","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.1528-1157.1999.tb01595.x","article-title":"Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism","volume":"40","author":"Eir\u00eds-Pu\u00f1al","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpag.2012.05.011_bib48","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/1531-8249(199904)45:4<444::AID-ANA5>3.0.CO;2-6","article-title":"Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy","volume":"45","author":"Vainionpaa","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpag.2012.05.011_bib49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/WNF.0b013e31823429a7","article-title":"Thyroid adverse effects of psychotropic drugs: a review","volume":"36","author":"Bou Khalil","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jpag.2012.05.011_bib50","series-title":"Pediatric Psychopharmacology","first-page":"297","article-title":"Mood stabilizers: lithium, anticonvulsants, and others","author":"Kowatch","year":"2011"},{"key":"10.1016\/j.jpag.2012.05.011_bib51","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/archpsyc.64.9.1032","article-title":"National trends in the outpatient diagnosis and treatment of bipolar disorder in youth","volume":"64","author":"Moreno","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib52","first-page":"835","article-title":"Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy","volume":"249","author":"Isojarvi","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpag.2012.05.011_bib53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jpag.2012.05.011_bib54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.21411","article-title":"Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine","volume":"64","author":"Morrell","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpag.2012.05.011_bib55","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.biopsych.2005.10.017","article-title":"Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder","volume":"59","author":"Joffe","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0920-1211(00)00139-X","article-title":"Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women","volume":"41","author":"Bauer","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jpag.2012.05.011_bib57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(01)00317-5","article-title":"Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate","volume":"48","author":"Luef","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jpag.2012.05.011_bib58","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/BF03348013","article-title":"Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy","volume":"20","author":"Murialdo","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jpag.2012.05.011_bib59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2011.07.006","article-title":"A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy","volume":"97","author":"Hu","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jpag.2012.05.011_bib60","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1210\/en.2003-0940","article-title":"Valproate potentiates androgen biosynthesis in human ovarian theca cells","volume":"145","author":"Nelson-DeGrave","year":"2004","journal-title":"Endrocrinology"},{"key":"10.1016\/j.jpag.2012.05.011_bib61","first-page":"341","article-title":"Temporolimbic epilepsy and polycystic ovary syndrome","volume":"43","author":"Herzog","year":"1996","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jpag.2012.05.011_bib62","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4088\/JCP.v67n0218","article-title":"Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls","volume":"67","author":"Joffe","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1399-5618.2005.00201.x","article-title":"Reproductive function and risk for PCOS in women treated for bipolar disorder","volume":"7","author":"Rasgon","year":"2005","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jpag.2012.05.011_bib64","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/01.WNL.0000106942.35533.62","article-title":"Long-term reproductive endocrine health in young women with epilepsy during puberty","volume":"62","author":"Mikkonen","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jpag.2012.05.011_bib65","first-page":"1001","article-title":"ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces Practice Bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation","volume":"111","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2012.05.011_bib66","first-page":"502","article-title":"Sexuality, pregnancy, and child- bearing among women with schizophrenia-spectrum disorders","volume":"47","author":"Miller","year":"1996","journal-title":"Hosp Community Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib67","first-page":"1","article-title":"Update on overall prevalence of major birth defects","volume":"57","year":"2008","journal-title":"MMWR Weekly"},{"key":"10.1016\/j.jpag.2012.05.011_bib68","series-title":"Pediatric Psychopharmacology","first-page":"313","article-title":"Psychopharmacology during pregnancy: infant considerations","author":"Epperson","year":"2011"},{"key":"10.1016\/j.jpag.2012.05.011_bib69","first-page":"42","article-title":"The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics","volume":"63","author":"Ernst","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib70","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1471-0528.2009.02141.x","article-title":"The management of epilepsy in pregnancy","volume":"116","author":"Walker","year":"2009","journal-title":"BJOG"},{"key":"10.1016\/j.jpag.2012.05.011_bib71","first-page":"967","article-title":"Mood stabilizers in pregnancy: a systematic review","volume":"44","author":"Galbally","year":"2010","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib72","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1176\/ajp.153.5.592","article-title":"Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines","volume":"153","author":"Altshuler","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib73","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpag.2012.05.011_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2005.06.001","article-title":"Children exposed to valproate in utero: population based evaluation of risks and confounding factors for long-term neurocognitive development","volume":"65","author":"Eriksson","year":"2005","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jpag.2012.05.011_bib75","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/YCO.0b013e3283413451","article-title":"Drug treatment for mood disorders in pregnancy","volume":"24","author":"Gentile","year":"2011","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2850.2009.01481.x","article-title":"Antipsychotics in pregnancy","volume":"17","author":"McCauley-Elsom","year":"2010","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"10.1016\/j.jpag.2012.05.011_bib77","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/schbul\/sbn107","article-title":"Antipsychotic therapy during early and late pregnancy. A systematic review","volume":"36","author":"Gentile","year":"2010","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jpag.2012.05.011_bib78","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4088\/JCP.v66n0406","article-title":"Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study","volume":"66","author":"McKenna","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib79","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.amjmed.2005.02.029","article-title":"Prescription of teratogenic medications in United States ambulatory practices","volume":"118","author":"Schwarz","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.jpag.2012.05.011_bib80","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-147-6-200709180-00006","article-title":"Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women","volume":"147","author":"Schwarz","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpag.2012.05.011_bib81","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.amjmed.2010.05.009","article-title":"Adherence to oral contraception in women on Category X medications","volume":"123","author":"Steinkellner","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jpag.2012.05.011_bib82","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yebeh.2004.11.006","article-title":"Knowledge of women\u2019s health issues and epilepsy (KOWIE-II): a survey of health care professionals","volume":"6","author":"Long","year":"2005","journal-title":"Epilesy Behav"},{"key":"10.1016\/j.jpag.2012.05.011_bib83","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4088\/JCP.08m04212","article-title":"Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study","volume":"70","author":"McIntyre","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpag.2012.05.011_bib84","series-title":"Pediatric Psychopharmacology","first-page":"50","article-title":"Cytochrome P450-mediated drug interactions","author":"Oesterheld","year":"2011"},{"key":"10.1016\/j.jpag.2012.05.011_bib85","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/13625187.2010.532252","article-title":"Reproductive and contraceptive issues in chronically ill adolescents","volume":"15","author":"Bacopoulou","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.jpag.2012.05.011_bib86","first-page":"1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4th edition","volume":"59","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jpag.2012.05.011_bib87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2010.06.013","article-title":"The use of hormonal contraception among women taking anticonvulsant therapy","volume":"83","author":"Gaffield","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2012.05.011_bib88","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.2010.03880.x","article-title":"The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine","volume":"71","author":"Haslemo","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpag.2012.05.011_bib89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00004714-200212000-00013","article-title":"Colazpine and oral contraceptives: a possible drug interaction","volume":"22","author":"Gabbay","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpag.2012.05.011_bib90","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1212\/01.wnl.0000344167.78102.f0","article-title":"Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use","volume":"72","author":"Herzog","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jpag.2012.05.011_bib91","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1528-1167.2007.00997.x","article-title":"Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial","volume":"48","author":"Christensen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpag.2012.05.011_bib92","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.yebeh.2009.01.024","article-title":"Antiepileptic drugs: are women are of interactions with oral contraceptives and potential teratogenicity?","volume":"14","author":"Pack","year":"2009","journal-title":"Epilepsy Behav"}],"container-title":["Journal of Pediatric and Adolescent Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083318812000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083318812000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:40:01Z","timestamp":1761054001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083318812000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1083318812000940"],"URL":"https:\/\/doi.org\/10.1016\/j.jpag.2012.05.011","relation":{},"ISSN":["1083-3188"],"issn-type":[{"value":"1083-3188","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gynecologic and Reproductive Health Concerns of Adolescents Using Selected Psychotropic Medications","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric and Adolescent Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpag.2012.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}